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ProteinZisaplasmaproteinfunctioningasacarrierforZPI.ProteinZalsoacceleratesinhibitoryeﬀectofZPIonfactorXaby1000-
fold. Inhibition of coagulation cascade via FXa by ZPI and other serpins is very important safety factor for normal homeostasis
protecting human life against unwanted thrombosis. In the present work using native structure of PZ, ZPI, FXa and in a dynamic
simulation, using NAMD software, the ternary complex was studied in an up to 10 nanoseconds protocol. Rely on trajectory
analyses, we postulated that PZ binds ZPI by using its SP-like domain and through noncovalent forces. PZ then transfers ZPI
through-out the blood, and by using its GLA domain and a bivalent cation of calcium, PZ binds to phospholipid bilayers (e.g.,
platelet) where the FXa is preallocated. In case of PZ-ZPI binding to plasma membrane, a series of complementary interactions
take place between FXa, and PZ-ZPI complex including interactions between RCL loop of ZPI and catalytic site of FXa and some
take place between long arm of PZ (composed of GLA, EGF1, and EGF2 domains) and GLA domain of FXa. In our claim these
complementary interactions lead PZ to bind correctly to prelocated FXa.
1.Introduction
Human protein Z, that is, PZ, is a single-chain plasma glyco-
protein which has been synthesized in liver and endothelial
cells with 62-KD and 360 residues [1]. PZ has plasma con-
centration of 2.9±1.0μg/mL [2, 3]. In the primary structure
of PZ, there are four distinct and consecutive domains,
which from N- to C-terminus, respectively, are named GLA,
EGF1, EGF2, and SP-like domains. GLA domains, which
include residues 1–46, contains 13 gamma carboxy glutamic
acid,GLA,whichhavebeenformedbyvitamin-K-dependent
posttranslational carboxylation of relevant glutamic acid
residues. GLA domain also contains a single disulphide
bridge between Cys18 and Cys23 [4–9]. GLA domain plays
an important role in PZ physiological function. Negatively
charged GLA domain using bivalent cation of Ca+2 helps
PZ to bind to negative groups of phospholipid membranes,
where PZ acts as a cofactor for FXa inhibition by ZPI.
However PZ with low content of GLA lacks cofactor activity
[4, 5, 10–12]. It was also shown that GLA domain accelerates
PZ interaction with FXa on phospholipid bilayers by about
6 times faster [10, 13]. The next two domains in PZ
are epidermal-growth-factor-like domains, EGF1 and EGF2.
EGF1 is stretched from residue 47 to 83 and EGF2 is located
between residue 85 and 126. Each of which contains 3 disul-
phide bonds. The last domain in PZ is serine-protease-like
(SP-like)domainbeginningfromresidue135andcontinuing
to the last residue of PZ (C-terminal residue number 360).
SP-like domain of PZ has two disulphide bonds which is
thought to have an active site resembling that of the triad
active site of serine protease family. Serine protease enzymes
such as FVII and FIX in their triad active site contain His57,
Asp162, and Ser195, which are essential for catalytic activity,
butincontrast,inPZHisandAsp,havebeenreplacedbyThr
and Ala, respectively [8–10, 14–17]. Human ZPI is a serine
protease inhibitor (serpin), synthesized predominantly in2 ISRN Hematology
liver, with about 25–30% sequence homology to other
serpins such as antithrombin III (AT3) [18–21]. ZPI makes
a complex with PZ in plasma with dissociation constant of
7nM [22]. PZ/ZPI complex is more eﬀective than ZPI in
inhibition of FXIa and FIXa [14, 18]. ZPI in its primary
structure contains three beta sheets named A, B, and C,
eight to nine alpha helices, hA,...,hI, and a reactive RCL
loop which is composed of four residues, Thr385-Ser388,
also known as P3-P1  (P3-P2-P1-P1 ) in the Scheeter-Berger
nomenclature method. ZPI inhibits FXa through comple-
mentary binding of RCL loop and interaction with catalytic
site of FXa resulting in ZPI-FXa complex formation [11, 23–
26]. However ZPI-FXa complex is unstable because FXa
proteolytically cleaves RCL loop of ZPI at P1 (Tyr387) site,
andtheproductsarereleasedfromFXaactivesite,[13,27].In
addition to the stereospeciﬁc interaction between RCL loop
of ZPI and FXa active site, the speciﬁcity of FXa inhibition by
ZPI is guaranteed by additional exosite interactions between
ZPI body and FXa surface residues. In this context there are
several electrostatic interactions between positively charged
groupsofautolysisloop(residues143–154anditsproximity)
of FXa including Lys96, Arg143, and Lys147 with negatively
charged groups on complementary region on ZPI including
Glu313, Glu231, andAsp233, respectively[24,28].Since FXa
inhibition by ZPI in the presence of PZ is increased 1000 fold
and there are miscellaneous reports showing that PZ itself
interact with FXa, then it had been postulated that PZ may
have diﬀerent function in FXa inhibition by ZPI:
(1) making stable complex with ZPI and act as plasma
carrier for ZPI,
(2) helping ZPI to immobilize on phospholipid mem-
brane where the FXa is ﬂanked,
(3) participating in targeting and docking of ZPI on FXa,
to aid the stereospeciﬁc interactions between ZPI and
FXa [10, 13, 22, 27, 28].
The precise mechanism of PZ-mediated promotion of
FXa by ZPI and also the molecular-/atomic-level events of
this phenomenon are not well understood. The main
scope of the present work is to mechanistically survey the
successive interaction of PZ, ZPI, and FXa, using molecular
dynamical approach by carrying out diﬀerent simulations.
Wedecidedtostudythetimecourseeventinhopetoapprove
the postulated mechanism and to extract more details of
molecular interaction.
2. Method and Material
2.1. Coordination Files Sources and System Setup. Optimized
full-length PZ coordination ﬁles including GLA domain and
calciumwereobtained asagiftfromProfessorPedersen[29].
ZPI and FXa ﬁles were obtained from protein data bank with
PDB ID 3H5C and 2XBY, respectively [30, 31].
2.2. Complex Preparation. Binary complex of PZ-ZPI was
constructed by superimposing residue 1–86 of full-length
PZ protein to same residues in protein 3H5C which consist
of PZ-ZPI complex lacking GLA of PZ by VMD software
[32]. Ternary complex of PZ-ZPI-FXa was constructed by
docking optimized structure of FXa with PDB ID of 2XBY
to 10 nanoseconds simulated binary complex of PZ-ZPI. By
using HEX 6.3 software, we docked FXa to ZPI in such a
way to put RCL loop of ZPI inside FXa catalytic site. Also
the best positions with lowest energy have been chosen for
further studies [33] ,a n dt r a j e c t o r ya n a l y s e sw e r ed o n eb y
using VMD and Vega ZZ softwares [32–34].
2.3. Simulation Conditions. Proteins were placed in cubic
boxes with dimensions large enough to equilibrate the
protein within them, and the protein did not exit the box
during simulation. The box size of 63.17 × 95.22 × 111.34 ˚ A
is used for PZ, box size of 66.25 × 89.36 × 66.93 ˚ Af o rZ P I ,
and box sizes of 58.80 × 72.54 × 65.15 ˚ Af o rF X a .T h eb o x
size of 118.35 × 136.27 × 131.36 ˚ A and 127.02 × 127.86 ×
120.84 ˚ A were used for PZ-ZPI and PZ-ZPI-FXa complexes,
respectively. TIP3P water was used as aqueous medium [35].
All the systems were energy minimized for up to 10000
minimizationstepsinordertoremovebadcontactinprotein
structure. Na+ and Cl− ions were used as counterions for
neutralizing the net charges of proteins. To study the eﬀect
of calcium ions, we simulate the entire system containing PZ
protein with its GLA domain in the absence and the presence
of 11 calcium ions. All the simulations were done in NPT
conditions for 310K of temperature and 1.0atm. of pressure,
and Particle mesh Ewald (PME) algorithm was applied to
calculate electrostatic forces in our systems. The cutoﬀ of 12
angstrom and time step of 2fs were used in all simulations
[36].
Molecular dynamic calculation of single proteins and
their complex in solution was performed using NAMD 2.7,
as a parallel code designed for high-performance simulation
oflargebiologicalmacromolecules,usingCHARMM27force
ﬁled [36, 37].
3. Results and Discussion
In order to study the mechanism by which PZ accelerates
ZPI to inhibit FXa, we simulate PZ, ZPI, FXa, PZ-ZPI binary
complex, and PZ-ZPI-FXa ternary complex in separated
simulation. Figure 1(a) shows the changes in root mean
squaredisplacement(RMSD)ofPZduringsimulationforup
to 10ns.
RMSD change of PZ conﬁrms system stability during
simulation. There are continuous small jumps in RMSD
appearing each 2ns of simulation and followed by a new
stability state. Trajectory movie shows that these jumps in
RMSD is caused by the bending of the long arm of PZ which
contains EGF1, EGF2, and GLA domains. The bending
movement seems to be restricted in some cases: (1) in case of
binding of calcium to GLA domain, (2) in the case of binary
complex formation between PZ and ZPI, and (3) in the case
of ternary complex formation with ZPI and FXa. Figure 1(b)
shows the root mean square ﬂuctuation, or RMSF, of each
atom during simulation for PZ in the presence and in the
absence of calcium ions. There are two hot regions with highISRN Hematology 3
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Figure 1: (a) Root mean square displacement (RMSD) of backbone to backbone for free PZ protein in aqueous solution at 310K and 1
atmosphere of pressure. (b) Root mean square ﬂuctuation (RMSF) for each alpha carbons of PZ in the presence (blue) and absence (red) of
calcium ions.
ﬂuctuatingRMSF.Theﬁrstregionbelongsto ∼45residuesof
N-terminal residues which move freely during simulation.
The second region, which appears as a sharp band at
residues 135–146, is at the beginning of SP-like domain. This
region is acting as ﬂexible hinge forming a bending arm for
PZ [38]. When calcium ions bind to GLA domain or when
PZ makes binary or ternary complexes with ZPI or ZPI-FXa,
respectively, the band altitude decreased prominently. We do
hypothesize that this ﬂexible arm may help PZ to match
bettercounterproteinsincomplexformation.Itisreasonable
toexpectthattheassociationoftwocomplementaryproteins
reduces the RMSF of their hot points.
Figure 2(a) shows the RMSD of free ZPI. RMSD plot
for ZPI for up to 10 nanoseconds indicates the stability
statewithoutanyunwantedperturbations.Figure 2(b)shows
RMSF of ZPI complex with PZ and to PZ-FXa. RMSF
changesofZPIintroducetwoﬂexiblepointsinZPIstructure,
as shown. The ﬁrst ﬂexible point placed at the proximity
of residue 139 and is the second at reactive center loop
(RCL)ofZPIaroundresidue384[39].Figure 2(b)alsoshows
that PZ binding to ZPI increases the ﬂexibility of these two
points. Accordingly it could be concluded that upon PZ
binding to ZPI, the increased ﬂexibility of these two points
facilitates ZPI binding to FXa. The binding of ZPI to FXa,
as is expected, decreases RMSF ﬂuctuation especially in RCL
loop, the FXa catalytic binding site.
The backbone RMSD changes of binary and ternary
complexes during simulation in the presence of calcium ions
are shown in Figure 3. RMSD changes for ternary complex
show more stability of the complex system in comparison to
binary complex. More stability of ternary complex conﬁrms
the eﬀectiveness of ternary complex or inhibitory complex of
PZ-ZPI-FXa formation in contrast to binary complex.
Figure 4 shows the PZ dipole moment changes in the
presence and absence of calcium ions. The curve shows that
at the presence of calcium ions the dipolmoment of PZ
decreased signiﬁcantly. GLA domain has 13 GLA residues
each with two negative charges and makes a strong dipole
moment with negative head arranged toward membrane
phospholipids which builds up huge repulsive force pre-
venting GLA binding to phospholipids bilayer. Binding of
calcium to GLA decreases its dipole moment and even
converts this repulsive force to an attractive force thereby
facilitates PZ binding to phospholipids bilayer through GLA
domains. This ﬁnding is in complete agreement with Rezaie
experimental ﬁndings who had reported that PZ participate
in ZPI targeting to phospholipids membranes where the FXa
is ﬂanked. In this way PZ increases the local concentration of
ZPI 1000-fold [13, 28, 40].
Figure 5(a) shows the changes in distance between center
of mass of PZ and ZPI in PZ-ZPI complex during simulation
in the presence and absence of calcium ions. The curve
shows that in the presence of calcium ions, and after 6ns of
simulation, the distance is decreased and the two proteins
become attracted to each other. Figure 5(b) illustrates the
changes in distance between two N-termini of PZ and ZPI
during simulation in the presence and absence of calcium
ions. As it could be seen, this distance decreased signiﬁcantly
after 4ns and the two N-termini of PZ and ZPI are pulled
to each other along PZ axis. Figures 5(a) and 5(b) reveal
thatthepresenceofcalciumion causesZPIattractiontoward
PZ center of mass and sliding down PZ axis, to proximity
of GLA domain and to the place where FXa is immobilized
on phospholipids membrane. This is facilitating ternary
complex formation with FXa, an inhibitory complex. It had
been shown that PZ not only participates in ZPI targeting
toward phospholipids membrane but also activates ZPI
with RCL loop pushed out from beta sheet and become
suitable for entrance into catalytic site of FXa [30]. Our
ﬁndings show that the distance between Ser388, a residue4 ISRN Hematology
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Figure 2: (a) Root mean square displacement (RMSD) of free Z-dependent protease inhibitor (ZPI) obtained in aqueous solution at 310K
and 1 atmosphere of pressure and a total time of 10ns. (b) Root mean square ﬂuctuation (RMSF) of all residues of free ZPI (violet), ZPI in
PZ-ZPI complex (black) and in ternary complex of PZ-ZPI-FXa (orange) at 10ns of simulation.
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Figure 3: Root mean square displacement (RMSD) of binary com-
plex of PZ-ZPI and ternary complex of PZ-ZPI-FX for up to 10ns
in aqueous solution at 310K and 1 atmosphere of pressure.
from RCL, to Asp102 (hydrogen-binding counterresidue), a
residue from FXa, is decreased during simulation, and these
two residues become in close proximity and imply that PZ
binding aﬀects RCL loop entrance to FXa active site [39, 40].
It had been reported that mutation in Arg255 of PZ in-
activates ZPI function. Pederson relied on these reports and
using molecular dynamic simulation and wild-type and mu-
tated PZ (Arg255→His255), postulated that Arg255 in PZ
is hydrogen bonded to Arg319 and Glu320 of PZ, so its
replacement with His weakens this hydrogen binding and
disturbs inhibitory eﬀect of ZPI on FXa [29]. Our simulation
data are presented in Table 1.
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Figure 4: Dipolmoment changes of PZ in the presence (cyan) and
absence (black) of calcium ions during simulation for up to 10ns.
Though the distance between alpha carbons of Arg255
and Arg319 and Glu320 before and after simulation is lesser
than that between other neighboring residues, the distance
between potential groups for hydrogen bond formation is
not necessarily the same. Our data show that functional
groups of Glu92 are more accessible for hydrogen binding
because of their closer vicinity to Arg255, 1.68 ˚ A against
3.27 ˚ A. The last frame of 100 nanoseconds trajectory shows
that this stable hydrogen bond is very important for the ﬁnalISRN Hematology 5
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Figure 5: (a) Changes in the distance between center of mass of PZ and ZPI in binary complex in the presence and absence of calcium ions
during simulation. (b) Changes in the distance between two N-termini of PZ and ZPI during simulation in the presence and absence of
calcium ions.
Table 1: The distance between alpha carbon of Arg255 and alpha carbons of three residues including Glu92, Glu320, and Arg319 are
presented in angstrom. The distance between functional group of Arg255 and nearer functional groups of each of residues Glu92, Glu320,
and Arg319 capable of forming hydrogen bonds is also included.
Residue
Cα-Cα distance (˚ A) Hydrogen-binding groups distance (˚ A)
Before simulation After simulation Before simulation After simulation
Arg255-Glu92 13.35 10.04 1.68 3.27
Arg255-Glu320 10.49 11.04 8.67 8.78
Arg255-Arg319 9.94 10.06 5.94 6.68
conformation of ternary complex and is placed in critical
point of PZ arm near the ﬂexible hinge. This hydrogen bond
is also participating in PZ conformation and reduction of
RMSF ﬂuctuation.
Figure 6 shows the changes in hydrophobic solvent-
accessible surface (SAS) of ternary complex during simula-
tion in the presence and absence of calcium ions. Decrease in
hydrophobic SAS, which implies the increase in hydrophilic
SAS of ternary complex of PZ-ZPI-FXa, indicates that in the
presence of calcium ions the complex changed to functional
complex with more hydrophilic interaction, for example,
more hydrogen bonds and more hydration of proteins
charged groups by surrounding solvent. These data indicate
the formation of more folded, more hydrophilic ternary
complex during simulation. It had been postulated that the
eﬃciency of complex formation between FXa and ZPI is
dependent ﬁrst on the speciﬁc interactions of RCL loop with
the active site of FXa and second on the complimentary
interactions between residues lying in the outer surface
of FXa body with counterpart groups on ZPI molecule.
The interactions of RCL loop and FXa active site act
as recognition tools for complex formation. P1 tyrosine
(Tyr387) enters the S1 active site of FXa ﬁrst then followed
by the insertion of RCL loop to active site, and afterward
miscellaneous interaction will be formed between P1–P3 
residues of ZPI and FXa active site residues. Rezaie had
shown that preincubation of PZ protein with calcium ions
promotes the rate of FXa inhibition by ZPI at least 5-
fold of magnitude. Rezaie also shows that PZ acts only on
membrane-bound FXa, and membrane binding of PZ is the
rate-limiting step in PZ-ZPI-FXa ternary complex formation
[13,30,39,40].Inglobularproteins,Rgorradiusofgyration,
is used as a measure of molecular radius.
Figure 7 exhibits the Rg variation of ternary complex
during simulation. As it could be expected, there is a
signiﬁcant time course decrease in Rg on complex when
it reaches the stable state. This decrement in Rg is in well
agreement with our ﬁndings regarding formation of a more
compacted,morehydrophilicternarycomplexinsimulation.
In this context, following up the changes in hydrogen bonds
during simulation gives us extra conﬁrmatory documents.
Our results show that running molecular dynamic simu-
lation itself causes the ternary complex to feel or sensate
the surrounding aqueous solution in such a way that their
functional groups changed and corrected their orientation
against water molecules and their nonbonded interactions.
Hydrogen bonds are one of the important nonbonded
interactions that are aﬀected under these circumstances, and
their count changed considerably. When the system reaches
the equilibrate state, the hydrogen bond count attains its6 ISRN Hematology
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Figure 6: Changes in hydrophobic solvent-accessible surface (SAS)
of the ternary complex of PZ-ZPI-FXa in the presence and absence
ofcalciumforupto10nsofsimulationinaqueoussolutionat310K
and 1 atmosphere of pressure.
47.5
48
48.5
49
49.5
50
50.5
51
51.5
52
52.5
0 6000 2000 4000 8000 10000
Time (ps)
+Ca+2
No Ca+2
G
y
r
a
t
i
o
n
 
r
a
d
i
u
s
 
(
˚
A
)
Figure 7: Changes in gyration radius (Rg) of the ternary complex
of PZ-ZPI-FXa in the presence and absence of calcium ions.
optimal number. Bringing equilibrated PZ, ZPI, and FXa
proteins to each other in a ternary complex and running
molecular dynamic simulation aﬀect hydrogen bonds count.
In a ternary complex of PZ-ZPI-FXa, there are three kinds
of hydrogen bonds populations that may change during
simulation: ﬁrst is intramolecular hydrogen bonds count as
H-bonds of PZ, ZPI, or FXa and second, intermolecular H-
bonds as H-bonds between PZ and ZPI, between ZPI and
FXa, and between PZ and FXa, and third is the hydrogen
bond between proteins and solvent.
Figure 8 displays the changes in hydrogen bond count
between the ﬁrst and the last frame of trajectory ﬁles of
simulated ternary complex. The main point in this ﬁgure
is the increase in intermolecular hydrogen bonds count
and increase in hydrogen bonds between ternary complex
with surrounding solvent at the expense of the decrease in
intramolecular hydrogen bonds.
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Figure 8: Changes in H-bonds counts calculated by subtracting the
H-Bond counts of the ﬁrst frame from last frame of trajectory ﬁle
of ternary complex of PZ-ZPI-FXa and are expressed as percent
of canges. Positive values indicate increased, and negative values
indicate decreased count of H-bonds.
4. Conclusion
Based on our ﬁndings and the previously postulated mecha-
nism for PZ-mediated FXa inhibition by ZPI, we conclude
that PZ, beside its action as plasma carrier for ZPI, by
using its SP-like domain, binds to ZPI through forming
noncovalent forces such as salt bridges and hydrogen bonds.
Negative charges of GLA domain of PZ make strong ionic
bonds with a positive charge of bivalent cation, calcium.
The next positive charge of calcium ions at the vicinity of
platelets membrane is used to bind GLA domain to negative
charges of platelet membranes. These interactions cause PZ
binding to the membrane probably where FXa has been
previously immobilized. PZ binding to membrane induces
conformational alterations including ZPI pulling down, RCL
loop of ZPI insertion into FXa active site, and formation of
active ternary complex of PZ-ZPI-FXa. The active complex
leads to catalytically cleavage of ZPI at P1 site and enzyme
inhibition [27, 30, 40].
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